Cayuga Biotech, a company that develops drugs that harness the body’s innate ability to heal and stop bleeding, today presented preclinical data on its first generation, first-in-class, polyphosphate (polyP)-based therapy designed to address life-threatening hemorrhage. The results demonstrated that the infused polyP-SNP (silica nanoparticle) complex was able to overcome conditions known to be associated with poor survival after injury with hemorrhage, known as the “lethal triad”—hemodilution, acidemia, and hypothermia. These data were presented as a poster presentation at the Military Health System Research Symposium in Kissimmee, FL.
“Bleeding is the leading cause of preventable death after traumatic injury in the battlefield, in large part due to the difficulty in treating non-compressible hemorrhage, such as from penetrating injury,” said Charles Pollack, MD, emergency medicine physician at the University of Mississippi and previously, Regimental Surgeon, 4th Marines, US Navy Medical Corps. “These data are exciting because this novel polyP-SNP complex can overcome some of the most challenging clinical conditions to help restore the ability to clot.”
Data presented in the “Technologies for the Treatment of Battlefield Hemorrhage and Management of Vascular Dysfunction” session demonstrated normalized thrombin generation and clotting under extreme hemodilute conditions in which normal plasma failed. Improved coagulation was also observed under severe acidotic and hypothermic conditions. As an injected drug that is inert in healthy tissue, the polyP-SNP complex travels via the bloodstream to any site of bleeding and acts to accelerate the clotting response without driving excess clotting, a problem that has limited development for other injectable drugs to treat hemorrhage.
Poster Session 1: “A synthetic short-chain polyphosphate (polyP) complexed with silica nanoparticle (SNP), corrects coagulopathy under hemodilute, hypothermic, or acidotic conditions”
About Hemorrhage
Nearly 2 million people globally per year die of hemorrhage, the majority of which is preventable. The top causes of preventable death by hemorrhage are non-compressible hemorrhage sites (such as internal bleeding and from penetrating injury) and delays in hemostatic control neither of which are adequately addressed by today’s current care model. Due to the nature of non-compressible hemorrhage sites, the complexity of clinical intervention is time consuming and delays in treatment often lead to patient death.
About Cayuga Biotech, Inc.
Cayuga is developing novel biomimetic therapies leveraging inorganic polyphosphate, a polymer that modulates the healing response. The company has an optimized polyP-SNP complex in late preclinical development for the treatment of acute major hemorrhage, a discovery-stage novel composition for the treatment of inherited bleeding disorders, as well as a portfolio of early-stage programs focused across the healing continuum. To learn more, please visit www.CayugaBiotech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827590394/en/